The Wall Street Journal: FDA may OK COVID boosters for 16- and 17-year-olds as soon as next week

The Food and Drug Administration could authorize COVID-19 boosters from Pfizer Inc.
PFE,
-2.96%

 and BioNTech SE
BNTX,
+4.17%

 for use in 16- and 17-year-olds as soon as next week as concerns rise over a new, possibly more transmissible variant, according to a person familiar with the planning.

The agency is planning to move rapidly to take action on a request by the companies to authorize boosters for 16- and-17-year-olds, according to a person familiar with the matter. So far, only people 18 years and older are eligible for boosters.

This post was originally published on Market Watch

Financial News

Daily News on Investing, Personal Finance, Markets, and more!